BACKGROUND: Some patients with non-small cell lung cancer (NSCLC) respond well to therapy with tyrosine kinase inhibitors (TKI). Somatic mutation of the epidermal growth factor receptor (EGFR) gene is an important predictive marker for TKI response. PATIENTS AND METHODS: We performed EGFR mutation analysis in 307 NSCLC (exon 18-21). The data were analyzed for associations with clinical-pathological parameters. RESULTS: Relevant EGFR mutations were found in 25/307 NSCLC (8.1%; 178 biopsies and 129 cytologies). Most mutations were found in exon 19 (50%) followed by the L858R point mutation in exon 21 (12.5%). EGFR mutations were significantly more common in women than in men (16.8% vs. 2.7%; p<0.001) and in adenocarcinoma than in other carcinoma subtypes (11.4% vs. 3.8%; p=0.017). EGFR mutation was associated with TTF-1 positivity (p<0.041). Almost all (96%) mutated NSCLC were TTF-1 positive. CONCLUSION: In Central Europe, the prevalence of relevant EGFR mutations in NSCLC is <10% of patients with NSCLC. EGFR mutations are more common in women and TTF-1 positive adenocarcinomas. Mutation analysis can be performed both from biopsies and cytologies.
BACKGROUND: Some patients with non-small cell lung cancer (NSCLC) respond well to therapy with tyrosine kinase inhibitors (TKI). Somatic mutation of the epidermal growth factor receptor (EGFR) gene is an important predictive marker for TKI response. PATIENTS AND METHODS: We performed EGFR mutation analysis in 307 NSCLC (exon 18-21). The data were analyzed for associations with clinical-pathological parameters. RESULTS: Relevant EGFR mutations were found in 25/307 NSCLC (8.1%; 178 biopsies and 129 cytologies). Most mutations were found in exon 19 (50%) followed by the L858R point mutation in exon 21 (12.5%). EGFR mutations were significantly more common in women than in men (16.8% vs. 2.7%; p<0.001) and in adenocarcinoma than in other carcinoma subtypes (11.4% vs. 3.8%; p=0.017). EGFR mutation was associated with TTF-1 positivity (p<0.041). Almost all (96%) mutated NSCLC were TTF-1 positive. CONCLUSION: In Central Europe, the prevalence of relevant EGFR mutations in NSCLC is <10% of patients with NSCLC. EGFR mutations are more common in women and TTF-1 positive adenocarcinomas. Mutation analysis can be performed both from biopsies and cytologies.
Authors: S Murray; E Timotheadou; H Linardou; A V Vrettou; I Kostopoulos; J Skrickova; C Papakostantinou; C Christodoulou; D Pectasides; E Samantas; P Papakostas; D V Skarlos; P Kosmidis; G Fountzilas Journal: Lung Cancer Date: 2006-03-29 Impact factor: 5.705
Authors: S Savic; C Tapia; B Grilli; A Rufle; M P Bihl; A de Vito Barascud; M Herzog; L Terracciano; F Baty; L Bubendorf Journal: Br J Cancer Date: 2007-12-18 Impact factor: 7.640
Authors: A Warth; L Bubendorf; S Gütz; A Morresi-Hauf; M Hummel; K Junker; U Lehmann; I Petersen; P A Schnabel Journal: Pathologe Date: 2013-07 Impact factor: 1.011
Authors: M Faehling; J Achenbach; P Staib; U Steffen; H W Tessen; V E Gaillard; W Brugger Journal: J Cancer Res Clin Oncol Date: 2018-04-23 Impact factor: 4.553
Authors: Juliana G Carneiro; Patricia G Couto; Luciana Bastos-Rodrigues; Maria Aparecida C Bicalho; Paula V Vidigal; Alyne Vilhena; Nilson F Amaral; Allen E Bale; Eitan Friedman; Luiz De Marco Journal: Genet Res (Camb) Date: 2014-03-05 Impact factor: 1.588
Authors: Christian Boch; Jens Kollmeier; Andreas Roth; Susann Stephan-Falkenau; Daniel Misch; Wolfram Grüning; Torsten Thomas Bauer; Thomas Mairinger Journal: BMJ Open Date: 2013-04-03 Impact factor: 2.692
Authors: Paweł Krawczyk; Rodryg Ramlau; Joanna Chorostowska-Wynimko; Tomasz Powrózek; Marzena Anna Lewandowska; Janusz Limon; Bartosz Wasąg; Juliusz Pankowski; Jerzy Kozielski; Ewa Kalinka-Warzocha; Aleksandra Szczęsna; Kamila Wojas-Krawczyk; Michał Skroński; Rafał Dziadziuszko; Paulina Jaguś; Ewelina Antoszewska; Justyna Szumiło; Bożena Jarosz; Aldona Woźniak; Wojciech Jóźwicki; Wojciech Dyszkiewicz; Monika Pasieka-Lis; Dariusz M Kowalski; Maciej Krzakowski; Jacek Jassem; Janusz Milanowski Journal: J Cancer Res Clin Oncol Date: 2014-08-03 Impact factor: 4.553
Authors: Albrecht Stenzinger; Jörn Sträter; Martin Faehling; Birgit Schwenk; Sebastian Kramberg; Robert Eckert; Anna-Lena Volckmar Journal: Oncotarget Date: 2017-09-13